Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SOD1 | P00441 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055639 | 0.91 | MAPT (0.50) | MAPTSOD1CYP2C19MAPK1MRGPRX4 | |
| SCHEMBL5043400 | 0.88 | MAPT (0.55) | MAPTSOD1CYP2C19TSHRDRD4 | |
| SCHEMBL5726229 | 0.86 | MAPT (0.46) | MAPTDRD4KCNH2KMT2AMAPK1 | |
| SCHEMBL2272070 | 0.83 | MAPT (0.59) | MAPTSOD1CYP2C19TSHRMAPK1 | |
| SCHEMBL17911632 | 0.83 | KCNA3 (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL10994640 | 0.81 | MAPT (0.57) | MAPTSOD1CYP2C19TSHRDRD4 | |
| SCHEMBL29434730 | 0.79 | DRD2 (0.58) | DRD4DRD2KCNH2KMT2ALMNA | |
| SCHEMBL2963485 | 0.79 | DRD2 (0.58) | DRD4DRD2KCNH2KMT2ALMNA | |
| SCHEMBL5978753 | 0.77 | MAPT (0.53) | MAPTSOD1CYP2C19TSHRDRD4 | |
| SCHEMBL8297095 | 0.77 | MAPT (0.59) | MAPTTSHRKMT2ASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765264-B1 | DENTAL COMPOSITION CONTAINING UNSATURATED CARBOSILANE CONTAINING COMPONENTS | MINNESOTA MINING MFG GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8003711-B2 | Dental composition containing Si-H functional carbosilane components | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003711-B2 | Dental composition containing Si-H functional carbosilane components | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-7662869-B2 | Curable di- or polyunsaturated carbosilane containing silicon-aryl bondand no silicon-oxygen bonds; initiator, filler, dyes, pigments, thixotropic agents, flow control agents, polymeric thickeners, surfactants, odorous substances, diluting agent(s) and flavors; crowns, bridges | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662869-B2 | Curable di- or polyunsaturated carbosilane containing silicon-aryl bondand no silicon-oxygen bonds; initiator, filler, dyes, pigments, thixotropic agents, flow control agents, polymeric thickeners, surfactants, odorous substances, diluting agent(s) and flavors; crowns, bridges | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080070193-A1 | Dental Composition Containing Unsaturated Carbosilane Containing Components | 3M DEUTSCHLAND GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070193-A1 | Dental Composition Containing Unsaturated Carbosilane Containing Components | 3M DEUTSCHLAND GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20070238803-A1 | Dental Composition Containing Si-H Functional Carbosilane Components | 3M DEUTSCHLAND GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238803-A1 | Dental Composition Containing Si-H Functional Carbosilane Components | 3M DEUTSCHLAND GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| EP-0946501-B1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6492412-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | disclosed |
| US-6344485-B1 | Method for treating glaucoma | PFIZER INC. | 2002-02-05 | — | — | US | disclosed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | disclosed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0066987-B1 | N-(ARYLOXYALKYL)-N'-(AMINO-ALKYL) UREAS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-08-27 | — | — | EP | disclosed |
| US-4558155-A | N-(Aryloxyalkyl)-N'-(aminoalkyl)thioureas | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| US-4500529-A | ANTIARRHYTHMIA AGENT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | MAPT 4871/4885SOD1 2802/4885CYP2C19 3236/4885 |
| US-20070238803-A1 | Dental Composition Containing Si-H Functional Carbosilane Components | TAS2R41, TAS2R42, TAS1R1 | MAPT 3226/4885SOD1 973/4885CYP2C19 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.